NASDAQ:IONS - Ionis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $52.19
  • Forecasted Upside: 66.84 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$31.28
▲ +1.03 (3.40%)

This chart shows the closing price for IONS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ionis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IONS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IONS

Analyst Price Target is $52.19
▲ +66.84% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $52.19, with a high forecast of $86.00 and a low forecast of $31.00. The average price target represents a 66.84% upside from the last price of $31.28.

This chart shows the closing price for IONS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in Ionis Pharmaceuticals. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 1 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 1 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 1 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 1 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 1 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2021Morgan StanleyLower Price TargetUnderweight$33.00 ➝ $31.00Low
8/19/2021BMO Capital MarketsLower Price TargetOutperform$70.00 ➝ $68.00Low
8/5/2021SVB LeerinkLower Price TargetMarket Perform$41.00 ➝ $38.00High
7/16/2021Morgan StanleyLower Price TargetUnderweight$35.00 ➝ $33.00Medium
5/14/2021SVB LeerinkBoost Price TargetMarket Perform$36.00 ➝ $41.00Medium
5/7/2021UBS GroupUpgradeSell ➝ Neutral$33.00 ➝ $37.50High
5/6/2021Morgan StanleyLower Price TargetUnderweight$38.00 ➝ $35.00High
4/19/2021Morgan StanleyLower Price TargetUnderweight$43.00 ➝ $38.00Low
4/5/2021UBS GroupReiterated RatingReduceHigh
3/23/2021BMO Capital MarketsLower Price TargetPositive ➝ Outperform$90.00 ➝ $76.00High
3/23/2021Needham & Company LLCLower Price TargetBuy$95.00 ➝ $86.00High
3/23/2021SVB LeerinkLower Price TargetMarket Perform$50.00 ➝ $36.00High
3/23/2021Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $43.00High
3/23/2021BarclaysLower Price TargetEqual Weight$52.00 ➝ $47.00High
3/23/2021Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$76.00 ➝ $65.00High
3/22/2021Piper SandlerLower Price TargetNeutral$55.00 ➝ $45.00High
3/16/2021UBS GroupReiterated RatingSell$33.00Medium
3/1/2021BarclaysUpgradeUnderweight ➝ Equal Weight$50.00 ➝ $52.00Low
2/25/2021Morgan StanleyBoost Price TargetUnderweight$49.00 ➝ $50.00High
2/24/2021Piper SandlerLower Price TargetNeutral$60.00 ➝ $55.00High
12/15/2020UBS GroupInitiated CoverageSell$34.00Medium
12/15/2020CowenUpgradeMarket Perform ➝ OutperformHigh
11/5/2020Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $49.00High
11/5/2020SVB LeerinkLower Price TargetMarket Perform$56.00 ➝ $50.00High
10/13/2020Morgan StanleyLower Price TargetUnderweight$54.00 ➝ $50.00Low
10/7/2020OppenheimerReiterated RatingBuy$69.00Low
9/22/2020OppenheimerInitiated CoverageBuy$69.00High
9/22/2020Cantor FitzgeraldBoost Price TargetNeutral$56.00 ➝ $59.00High
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
9/8/2020CitigroupLower Price Target$74.00 ➝ $78.00Low
9/2/2020BenchmarkInitiated CoverageHoldMedium
9/1/2020Royal Bank of CanadaBoost Price Target$71.00 ➝ $73.00Low
9/1/2020SVB LeerinkBoost Price TargetMarket Perform$54.00 ➝ $56.00Medium
9/1/2020OppenheimerLower Price TargetOutperform$74.00 ➝ $69.00Medium
9/1/2020Needham & Company LLCBoost Price TargetBuy$89.00 ➝ $91.00Medium
8/30/2020OppenheimerInitiated CoverageBuy$74.00High
8/10/2020CitigroupLower Price TargetBuy$80.00 ➝ $78.00High
8/6/2020Morgan StanleyLower Price TargetUnderweight$56.00 ➝ $54.00Low
8/6/2020OppenheimerReiterated RatingBuyLow
8/5/2020Needham & Company LLCInitiated CoverageBuy$89.00Low
8/5/2020William BlairReiterated RatingHoldLow
7/15/2020Morgan StanleyBoost Price TargetUnderweight$51.00 ➝ $56.00Low
7/15/2020Needham & Company LLCReiterated RatingBuy$89.00Medium
6/10/2020William BlairReiterated RatingHoldHigh
6/5/2020CitigroupBoost Price TargetBuy$71.00 ➝ $80.00High
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$71.00Medium
5/7/2020Morgan StanleyBoost Price TargetUnderweight$48.00 ➝ $51.00High
5/7/2020OppenheimerLower Price TargetOutperform$77.00 ➝ $74.00High
5/6/2020Needham & Company LLCReiterated RatingBuy$89.00High
4/9/2020CitigroupLower Price TargetBuy$73.00 ➝ $71.00Low
3/26/2020Cantor FitzgeraldLower Price TargetNeutral$65.00 ➝ $56.00High
3/9/2020JPMorgan Chase & Co.Boost Price TargetNeutral$58.00 ➝ $60.00Low
3/5/2020CitigroupInitiated CoverageBuy$73.00High
2/27/2020Piper SandlerLower Price TargetNeutral$70.00 ➝ $65.00High
1/30/2020BMO Capital MarketsReiterated RatingBuy$86.00High
1/24/2020William BlairReiterated RatingHoldLow
12/31/2019Bank of AmericaReiterated RatingBuy$70.00Medium
12/23/2019Needham & Company LLCReiterated RatingBuy$87.00Low
12/13/2019Needham & Company LLCReiterated RatingBuy$87.00Medium
12/12/2019OppenheimerInitiated CoverageBuy$77.00Low
11/14/2019William BlairInitiated CoverageMarket PerformLow
11/13/2019Bank of AmericaInitiated CoverageBuy$70.00Medium
11/7/2019Piper Jaffray CompaniesLower Price TargetNeutral$75.00 ➝ $70.00Medium
11/7/2019Needham & Company LLCReiterated RatingBuy$87.00Low
11/7/2019Morgan StanleyDowngradeEqual ➝ Equal Weight$63.00 ➝ $48.00Low
11/7/2019CowenReiterated RatingHoldLow
10/16/2019CowenReiterated RatingHoldHigh
10/15/2019Cantor FitzgeraldSet Price TargetHold$65.00N/A
10/11/2019Morgan StanleyLower Price TargetEqual Weight$68.00 ➝ $63.00Medium
10/10/2019Wells Fargo & CompanyBoost Price TargetOutperform$90.00 ➝ $120.00Medium
10/9/2019Needham & Company LLCSet Price TargetBuy$87.00Low
9/23/2019Wells Fargo & CompanyReiterated RatingBuyMedium
9/10/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$80.00High
8/7/2019Evercore ISISet Price TargetHold$76.00Low
7/24/2019BMO Capital MarketsLower Price TargetOutperform$96.00 ➝ $95.00Low
5/24/2019Piper Jaffray CompaniesSet Price TargetHold$75.00Medium
4/24/2019Cantor FitzgeraldReiterated RatingHold$68.00Low
4/22/2019BMO Capital MarketsBoost Price TargetOutperform$96.00Low
4/18/2019Cantor FitzgeraldReiterated RatingHoldLow
4/9/2019Cantor FitzgeraldInitiated CoverageNeutral$68.00Medium
3/22/2019Piper Jaffray CompaniesSet Price TargetNeutral$63.00 ➝ $75.00Low
3/18/2019JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$47.00 ➝ $55.00Low
3/1/2019Morgan StanleySet Price TargetHold$71.00Low
3/1/2019Piper Jaffray CompaniesSet Price TargetHold$63.00Low
2/28/2019Piper Jaffray CompaniesBoost Price TargetNeutral$60.00Low
2/28/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $82.00Low
11/27/2018SVB LeerinkInitiated CoverageMarket Perform$50.00High
11/7/2018Morgan StanleySet Price TargetHold$46.00Low
11/6/2018Piper Jaffray CompaniesSet Price TargetHold$50.00Medium
10/3/2018Morgan StanleySet Price TargetHold$45.00Low
9/25/2018Stifel NicolausBoost Price TargetHold ➝ Hold$45.00 ➝ $48.00High
9/24/2018Piper Jaffray CompaniesSet Price TargetHold$50.00Medium
8/28/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$49.00 ➝ $45.00Low
8/28/2018Stifel NicolausLower Price TargetHold ➝ Hold$47.00 ➝ $45.00High
8/8/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $49.00High
8/7/2018Stifel NicolausLower Price TargetHold ➝ Hold$55.00 ➝ $48.00High
7/11/2018Piper Jaffray CompaniesSet Price TargetHold$50.00Low
6/20/2018BarclaysDowngradeEqual Weight ➝ Underweight$52.00High
5/30/2018Piper Jaffray CompaniesInitiated CoverageHold$50.00Medium
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$52.00Low
5/7/2018Stifel NicolausLower Price TargetHold ➝ Hold$57.00Low
4/23/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00Medium
2/28/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$64.00 ➝ $65.00High
2/28/2018Stifel NicolausBoost Price TargetHold ➝ Hold$55.00 ➝ $57.00High
2/20/2018Sanford C. BernsteinReiterated RatingMarket Perform$61.00 ➝ $55.00Low
11/8/2017BMO Capital MarketsBoost Price TargetOutperform$64.00 ➝ $65.00N/A
11/8/2017Morgan StanleyBoost Price TargetEqual Weight$45.00 ➝ $49.00N/A
10/17/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
10/13/2017Stifel NicolausReiterated RatingHold$50.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingSell ➝ Sell$30.00N/A
10/2/2017BMO Capital MarketsReiterated RatingOutperform$69.00Medium
9/21/2017BarclaysLower Price TargetEqual Weight$55.00 ➝ $52.00Low
9/17/2017Needham & Company LLCReiterated RatingBuy$64.00Low
9/12/2017Stifel NicolausReiterated RatingHoldLow
9/6/2017BarclaysInitiated CoverageEqual Weight$55.00Medium
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$65.00Low
8/14/2017LaidlawReiterated RatingBuy$65.00Low
8/14/2017BMO Capital MarketsBoost Price TargetOutperform$67.00 ➝ $69.00Low
8/10/2017Jefferies Financial GroupReiterated RatingUnderperform$17.00 ➝ $18.00High
8/9/2017Stifel NicolausBoost Price TargetHold$42.00 ➝ $50.00Low
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$57.00High
7/26/2017Needham & Company LLCReiterated RatingBuy$64.00Medium
7/25/2017BMO Capital MarketsReiterated RatingOutperform$59.56 ➝ $62.00Low
7/12/2017BMO Capital MarketsReiterated RatingOutperform$59.00 ➝ $62.00Low
7/10/2017Stifel NicolausReiterated RatingHold$42.00Medium
6/2/2017BMO Capital MarketsReiterated RatingBuy$59.00Medium
5/22/2017CowenReiterated RatingMarket PerformLow
5/17/2017SVB LeerinkReiterated RatingOutperform$47.00 ➝ $45.00Medium
5/17/2017Needham & Company LLCReiterated RatingBuy$64.00Low
5/11/2017BMO Capital MarketsBoost Price TargetOutperform$32.00 ➝ $35.00High
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 ➝ $51.00Low
4/26/2017BMO Capital MarketsReiterated RatingOutperform$59.00Low
3/10/2017The Goldman Sachs GroupDowngradeNeutral ➝ Sell$28.00 ➝ $25.00High
3/7/2017BMO Capital MarketsLower Price TargetOutperform$63.00 ➝ $59.00N/A
3/6/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
2/28/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
2/14/2017BMO Capital MarketsReiterated RatingOutperform ➝ Positive$63.00N/A
1/17/2017BMO Capital MarketsReiterated RatingOutperform$68.00 ➝ $63.00N/A
1/8/2017BMO Capital MarketsReiterated RatingOutperform$68.00N/A
1/8/2017Needham & Company LLCReiterated RatingBuy$64.00N/A
1/6/2017CowenReiterated RatingHoldN/A
1/6/2017Jefferies Financial GroupReiterated RatingSell$17.00N/A
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/A
12/28/2016Janney Montgomery ScottReiterated RatingNeutral$50.00 ➝ $54.00N/A
12/28/2016BMO Capital MarketsBoost Price TargetOutperform$61.00 ➝ $68.00N/A
12/27/2016Needham & Company LLCReiterated RatingBuy$64.00N/A
12/27/2016LaidlawBoost Price TargetBuy$59.00 ➝ $65.00N/A
12/27/2016SVB LeerinkBoost Price TargetMarket Perform$40.00 ➝ $47.00N/A
12/20/2016BMO Capital MarketsSet Price TargetBuy$48.00 ➝ $61.00N/A
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$35.00N/A
11/10/2016SVB LeerinkReiterated RatingMarket Perform$40.00N/A
11/10/2016Jefferies Financial GroupReiterated RatingSell$17.00N/A
11/9/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
11/8/2016BMO Capital MarketsReiterated RatingBuy$48.00N/A
(Data available from 10/20/2016 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/22/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
8/21/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
10/20/2021

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Ionis Pharmaceuticals logo
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Read More

Today's Range

Now: $31.28
Low: $30.05
High: $31.87

50 Day Range

MA: $36.72
Low: $30.25
High: $40.55

52 Week Range

Now: $31.28
Low: $29.01
High: $64.37

Volume

1,964,716 shs

Average Volume

1,281,839 shs

Market Capitalization

$4.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

The following equities research analysts have issued research reports on Ionis Pharmaceuticals in the last year: Barclays PLC, BMO Capital Markets, Cowen Inc, Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, SVB Leerink LLC, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for IONS.

What is the current price target for Ionis Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Ionis Pharmaceuticals in the last year. Their average twelve-month price target is $52.19, suggesting a possible upside of 66.8%. Needham & Company LLC has the highest price target set, predicting IONS will reach $86.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $31.00 for Ionis Pharmaceuticals in the next year.
View the latest price targets for IONS.

What is the current consensus analyst rating for Ionis Pharmaceuticals?

Ionis Pharmaceuticals currently has 1 sell rating, 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IONS, but not buy more shares or sell existing shares.
View the latest ratings for IONS.

What other companies compete with Ionis Pharmaceuticals?

How do I contact Ionis Pharmaceuticals' investor relations team?

Ionis Pharmaceuticals' physical mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company's listed phone number is (760) 931-9200 and its investor relations email address is [email protected] The official website for Ionis Pharmaceuticals is www.ionispharma.com.